MDNews - Mid Penn

Innovations 2019

Issue link: https://viewer.e-digitaledition.com/i/1177726

Contents of this Issue

Navigation

Page 6 of 15

THE RISKS AND BURDENS OF STANDARD CARE A non s u r g ic a l t r e at ment wou ld b e w e l c o m e n e w s f o r p a t i e n t s w i t h N MIBC, which is a common form of bladder cancer — the six th most com- mon cancer in the United States, with more than 80,000 new cases expected in 2019, according to the National Cancer Institute. Bladder cancer is, primarily, a disease of older populations. People ages 55 or older comprise 92% of cases, and the average age at diagnosis is 73. Ma ny individua ls with NMIBC with intermediate likelihood of recurrence have comorbidities that can make stan- dard care — typica lly, cystoscopy with an electrocauter y device to resect the tumor, of ten followed by intravesica l therapy — risky. "Of ten, patients a re ta king a ntico- agulants, so there's a risk of bleeding," Dr. Raman says. "Many patients need a catheter to remain in the bladder after surger y, which increa ses t he r isk of infection. Additiona lly, multiple pro- cedures lead scar tissue to form in the bladder that may reduce its ability to contract and can cause chronic pain." A POTENTIALLY GAME-CHANGING OPTION T h e n a t i o n w i d e s t u d y o f U G N - 1 0 2 's e f f i c a c y a n d s a f e t y b e g a n i n O c t o b e r 2 01 8 a n d i s s c h e d u l e d t o c o n c l u d e i n S e p t e m b e r 2 0 2 0 . Resea rchers pla n to recr uit approx i- mately 60 patients. Penn State Hea lth ha s en rol led t h ree pa r t icipa nt s a nd would like to register three to four more. Participants receive UGN-102 weekly for si x we ek s . W hen s t or e d a t c o ol temperatures, UGN-102 is liquid, but ex posure to body temperatures turns it gelatinous. That tra nsition is a key d i f ferentiator compa red w it h l iqu id dr ugs used to treat bladder tumors. " L iqu id chemot herapeut ic a gent s t h a t a r e s t a n d a r d of c a r e m a y n o t c ont a c t a l l p or t ion s of t he bl a dder because they may settle at the bottom," Dr. R a m a n say s. " T he d r u g m ay not reach the nondependent por tion of the bladder. With UGN-102, the gel covers the entire bladder wa ll a nd sticks to it." C y s t o s c opie s a t t h r e e , s i x , n i ne a nd 12 months af ter treatment a llow u r olo g i s t s t o a s s e s s p a r t i c ip a nt s ' responses. Individua ls who have not responded to treatment can transition to standard surgical care. Researchers and patients have reason to be optimistic about UGN-102's potential: The product's developer announced earlier this year that in a phase 3 clinical trial of a mitomycin gel formulation to treat low-grade upper- tract urothelial cancer, 57% of patients were cancer-free four to six weeks after treatment. A ll of the participants who were cancer-free and continued to be evaluated showed no signs of the disease six months after treatment. For Dr. Raman, the UGN-102 trial is evi- dence of Penn State Health's willingness to embrace innovation in pursuit of effective, less invasive treatments for patients. " Under t a k i n g t r i a l s l i ke t h i s one shows we're w i l li ng to t h i n k beyond the sta nda rd of ca re we currently offer a nd ex plore how to improve treatment for N MIBC," Dr. R a ma n says. " Being one of 25 pa r ticipating centers in the countr y hig h lig hts our excel lence in bladder ca ncer a mong our peers." For information about the Division of Urology at Penn State Health Milton S. Hershey Medical Center, visit hmc. pennstatehealth.org/urology. n Comprehensive, Leading-Edge Urology Care IN HIS 11-YEAR tenure at Penn State Health, Professor and Chief of Urology Jay Raman, MD, FACS, has watched the Division of Urology at Penn State Health Milton S. Hershey Medical Center expand from a handful of urologists to 23 physicians and advanced practice providers, including 12 subspecialists in areas such as urologic oncology and pediatric urology, as well as men's health, impotence, male infertility and urinary stone disease, among others. That depth of expertise allows Penn State Health to offer advanced treat- ments for the gamut of urologic diseases. "The UGN-102 clinical trial for bladder cancer highlights our expertise in treating that disease, and we also offer trials for more advanced, large-volume bladder cancer," Dr. Raman says. "We take pride in offering care that may not be available in the community, including for prostate cancer — robotic-assisted biopsies and mini- mally invasive robotic surgeries using the latest iteration of the da Vinci Surgical System — as well as benign pros- tatic hyperplasia." Rated a top 50 facility for adult urology for 2019–20 by U.S. News & World Report, Penn State Health Milton S. Hershey Medical Center is a resource and partner in care for community primary care physicians and urologists in central Pennsylvania. "We establish collaborative relationships with physicians who refer patients to us," Dr. Raman says. "Our urologists have the skill sets to manage common urologic conditions and ones that would benefit from more complex or emerging forms of treatment, such as those offered in clinical trials. Penn State Health has across-the-board resources to be an effective part- ner and outlet for our colleagues in the communities we serve." M D N E W S . C O M /// M D N E W S M I D - P E N N ■ 2 019 0 7

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Mid Penn - Innovations 2019